Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Cellectis S.A. (ALCLS.PA)
Paris, FR
Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and headquartered in Paris, France, concentrates on immuno-oncology. The firm engineers therapeutic solutions utilizing gene-edited T-cells, which are modified to display chimeric antigen receptors (CARs) for the specific identification and destruction of cancer cells. Its operations are divided into two principal segments: Therapeutics and Plants. The company's pipeline features several allogeneic CAR T-cell product candidates. These include UCART19, aimed at CD19-expressing hematologic malignancies such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A, developed to treat relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316, targeting renal cell carcinoma; UCART123, for acute myeloid leukemia; and UCART22, addressing B-cell acute lymphoblastic leukemia. Additionally, Cellectis is advancing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. Cellectis has forged significant strategic partnerships and alliances with companies including Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. It also maintains a strategic research and development collaboration with Cytovia Therapeutics, Inc.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.32% | +10.88% | -4.11% | +7.19% | +10.53% | -15.52% | +166.77% | +110.81% | -71.43% | -86.68% | -75.96% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+82.9% ★ Q1'26: -46.7% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-70.7% Q1'26: +5.6% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-89.5% Q1'26: -194.6% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-55.3% Q1'26: -467.4% (vs Q1'25)
-
ROIC Biotechnology: -16.1%—
-
Share dilution Biotechnology: -3.4%+11.6% Q1'26: +0.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-5.68× Q1'26: -1.02× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2009 actual |
Dec 2010 actual |
Dec 2011 actual |
Dec 2012 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 1 EPS Ana. |
Dec 2027 5 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
17.32M
est: 14.55M (+19.0%)
|
20.98M
est: 17.97M (+16.7%)
|
20.73M
est: 23.50M (-11.8%)
|
27.81M
est: 28.37M (-2.0%)
|
55.04M
est: 33.34M (+65.1%)
|
42.58M
est: 48.96M (-13.0%)
|
25.19M
est: 35.48M (-29.0%)
|
12.73M
est: 27.27M (-53.3%)
|
15.19M
est: 23.37M (-35.0%)
|
73.95M
est: 63.11M (+17.2%)
|
73.95M
est: 61.15M (+20.9%)
|
19.17M
est: 34.45M (-44.4%)
|
755.0K
est: 30.56M (-97.5%)
|
41.51M
est: 40.29M (+3.0%)
|
75.92M
est: 77.96M (-2.6%)
|
58.87M
40.83M – 70.99M
-24.5% YoY
|
115.51M
33.87M – 305.30M
+96.2% YoY
|
71.80M
29.60M – 159.12M
-37.8% YoY
|
74.64M
30.76M – 165.40M
+3.9% YoY
|
158.09M
65.16M – 350.34M
+111.8% YoY
|
| EBITDA |
-12.25M
est: -10.88M (-12.6%)
|
-12.98M
est: -20.28M (+36.0%)
|
-24.50M
est: -22.16M (-10.5%)
|
-20.76M
est: -37.41M (+44.5%)
|
-29.22M
est: -46.91M (+37.7%)
|
-65.04M
est: -13.22M (-391.8%)
|
-100.31M
est: -97.57M (-2.8%)
|
-85.91M
est: -91.11M (+5.7%)
|
-105.73M
est: -68.43M (-54.5%)
|
-43.34M
est: -119.79M (+63.8%)
|
-85.44M
est: -258.23M (+66.9%)
|
-76.38M
est: -186.46M (+59.0%)
|
-92.64M
est: -305.96M (+69.7%)
|
-9.46M
est: -474.57M (+98.0%)
|
-21.12M
est: -54.67M (+61.4%)
|
-41.28M
-49.78M – -28.63M
+24.5% YoY
|
-81.00M
-214.09M – -23.75M
-96.2% YoY
|
-50.35M
-111.58M – -20.75M
+37.8% YoY
|
-52.34M
-115.98M – -21.57M
-3.9% YoY
|
-110.86M
-245.67M – -45.69M
-111.8% YoY
|
| EBIT |
-13.39M
est: -12.55M (-6.7%)
|
-14.70M
est: -23.62M (+37.8%)
|
-25.31M
est: -26.57M (+4.7%)
|
-25.61M
est: -42.76M (+40.1%)
|
-22.58M
est: -53.62M (+57.9%)
|
-67.25M
est: -32.67M (-105.8%)
|
-103.68M
est: -104.57M (+0.9%)
|
-88.29M
est: -76.34M (-15.6%)
|
-112.61M
est: -121.76M (+7.5%)
|
-51.18M
est: -170.07M (+69.9%)
|
-92.58M
est: -366.60M (+74.7%)
|
-94.81M
est: -264.72M (+64.2%)
|
-111.16M
est: -434.38M (+74.4%)
|
-29.31M
est: -673.75M (+95.7%)
|
-42.00M
est: -66.41M (+36.8%)
|
-50.15M
-60.47M – -34.78M
+24.5% YoY
|
-98.40M
-260.08M – -28.85M
-96.2% YoY
|
-61.17M
-135.55M – -25.21M
+37.8% YoY
|
-63.58M
-140.90M – -26.21M
-3.9% YoY
|
-134.68M
-298.45M – -55.51M
-111.8% YoY
|
| Net Income |
-5.52M
est: 272.4K (-2,126.0%)
|
-10.72M
est: -19.07M (+43.8%)
|
-30.90M
est: -19.06M (-62.1%)
|
-29.45M
est: -52.19M (+43.6%)
|
-22.46M
est: -65.45M (+65.7%)
|
-63.92M
est: -24.04M (-165.9%)
|
-99.37M
est: -104.50M (+4.9%)
|
-78.69M
est: -81.88M (+3.9%)
|
-90.69M
est: -91.17M (+0.5%)
|
-72.57M
est: -140.53M (+48.4%)
|
-86.28M
est: -302.92M (+71.5%)
|
-98.69M
est: -218.74M (+54.9%)
|
-101.06M
est: -358.93M (+71.8%)
|
-36.76M
est: -556.72M (+93.4%)
|
-70.35M
est: -76.75M (+8.3%)
|
-87.81M
-226.63M – -20.71M
-14.4% YoY
|
-71.63M
-184.87M – -16.89M
+18.4% YoY
|
-128.56M
-331.80M – -30.32M
-79.5% YoY
|
-144.55M
-373.05M – -34.09M
-12.4% YoY
|
-123.89M
-319.73M – -29.22M
+14.3% YoY
|
| SGA |
7.97M
est: 63.16M (-87.4%)
|
17.90M
est: 79.57M (-77.5%)
|
26.69M
est: 7.68M (+247.3%)
|
25.83M
est: 11.71M (+120.5%)
|
29.78M
est: 14.69M (+102.7%)
|
41.26M
est: 44.54M (-7.4%)
|
44.75M
est: 157.08M (-71.5%)
|
47.25M
est: 120.71M (-60.9%)
|
43.02M
est: 103.45M (-58.4%)
|
44.20M
est: 279.41M (-84.2%)
|
44.20M
est: 270.74M (-83.7%)
|
17.49M
est: 152.53M (-88.5%)
|
14.80M
est: 135.31M (-89.1%)
|
17.60M
est: 175.72M (-90.0%)
|
20.60M
est: 340.04M (-93.9%)
|
256.78M
178.09M – 309.64M
-24.5% YoY
|
503.84M
147.73M – 1.33B
+96.2% YoY
|
313.20M
129.09M – 694.06M
-37.8% YoY
|
325.55M
134.19M – 721.44M
+3.9% YoY
|
689.59M
284.23M – 1.53B
+111.8% YoY
|
| EPS |
-0.39
est: -0.10 (-277.3%)
|
-0.76
est: -0.55 (-39.1%)
|
-2.19
est: -0.61 (-258.3%)
|
-1.48
est: -0.78 (-88.8%)
|
-0.66
est: -0.89 (+26.2%)
|
-1.81
est: -1.78 (-1.9%)
|
-2.78
est: -2.61 (-6.4%)
|
-1.93
est: -2.58 (+25.1%)
|
-2.14
est: -2.59 (+17.4%)
|
-1.71
est: -2.30 (+25.6%)
|
-1.93
est: -3.07 (+37.2%)
|
-2.17
est: -2.40 (+9.7%)
|
-2.08
est: -1.20 (-73.5%)
|
-0.41
est: -0.61 (+33.0%)
|
-0.70
est: -0.77 (+8.5%)
|
-0.88
-2.26 – -0.21
-14.4% YoY
|
-0.71
-1.84 – -0.17
+18.4% YoY
|
-1.28
-3.31 – -0.30
-79.5% YoY
|
-1.44
-3.72 – -0.34
-12.4% YoY
|
-1.24
-3.19 – -0.29
+14.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Andre Choulika | Co-Founder, Chief Executive Officer & Director | 835.3K | — |
| David J. Sourdive | Co-Founder, Deputy Chief Executive Officer, Executive Vice President of CMC & Manufacturing and Director | 540.7K | — |
| Jean Charles Epinat | Chief Technological Officer | — | male |
| Kyung Nam-Wortman | Executive Vice President & Chief Human Resources Officer | — | female |
| Marie-Bleuenn Terrier | General Counsel & Secretary of the Board of Directors | — | female |
| Pascalyne Wilson | Director of Communications | — | — |
| Philippe Duchateau | Chief Scientific Officer | — | — |
| Stephan Reynier | Chief Regulatory & Pharmaceutical Compliance Officer | — | male |
| Valerie Cros | Principal Financial Officer & Principal Accounting Officer | — | — |
| Arthur Stril | Chief Financial Officer & Chief Business Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ALCLS.PA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
